Cryo-Save Group N.V. : Cryo-Save Group N.V. - Cord blood sample release for stem cell transplantation

 Cryo-Save Group N.V. : Cryo-Save Group N.V. - Cord blood sample release for
                          stem cell transplantation

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the
leading international stem cell storage company and the largest family stem
cell bank in Europe, announced a stem cell transplantation in Spain to treat
Blackfan-Diamond Aneamia. It is the first time in Spain that this congenital
anaemia, classified as a rare disease, has been treated using cord blood stem
cells which were stored with Cryo-Save.

A 4-year-old boy was treated for Blackfan-Diamond anaemia (BDA) with a stem
cell transplant from his sister's umbilical cord blood. The transplant was
performed on April 25 at the Hospital del Niño Jesús in Madrid, one of the
most important paediatric hospitals in Spain.
The transplantation was successful, and the child is expected to make a normal
recovery. This pioneering treatment in Spain may herald a radical improvement
in the child's quality of life, as since birth he has required regular red
blood cell transfusions.

"Up until the transplantation our life was bound to red blood cell
transfusions. We could hardly be happier, because now our son will be able to
lead a completely normal life", said Elena, the boy's mother. The parents had
only found out about the possibility of this type of treatment when Elena was
pregnant with her daughter, now the cord blood donor. "We had the opportunity
to heal our son, if the sample was compatible, and we could not forego it",
she said. "Our daughter will be very happy when she learns that her brother
got better thanks to her", she added.

"Blackfan-Diamond anaemia is a congenital disease that prevents the bone
marrow from producing the red blood cells needed to carry oxygen throughout
the body", explained Dr. Luis Madero, Head of the Oncohaematology Department
of the Hospital Niño Jesús in Madrid, and the physician who performed the
transplantation. Until recently, the main treatments were periodical red blood
cell transfusions, which clearly affects the patient's quality of life, and
long-term corticosteroid therapy, which is not tolerated in all cases. "The
transplantation of umbilical cord blood stem cells, especially between
siblings, is now a recommended treatment option for certain types of
haematological diseases, such as BDA. The benefits versus other treatments for
this disease are clear and confirmed by several studies", asserted Dr. Madero.

Arnoud van Tulder, Chief Executive officer, commented:
"We are very proud and pleased to have contributed to alleviating this
family's suffering. Cryo-Save strives to serve society by offering the highest
quality in stem cell cryopreservation and supporting innovative stem cell
therapies that could save lives and improve the quality of life of patients.

"This successful stem cell transplantation is another example of the
implementation of our mission, the quality of our internal procedures and
underlines the importance of storing umbilical cord blood stem cells for
potential family needs."


Cryo-Save Group, Arnoud van Tulder, Chief Executive Officer, + 31 (0) 575 509

Please click here for full press release in PDF


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Cryo-Save Group N.V. via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.